WTA
STRO icon

Washington Trust Advisors’s Sutro Biopharma STRO Stock Holding History

Washington Trust Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18
Closed -$768 – 675
2023
Q4 		$768 Hold
18
– – ﹤0.01% 660
2023
Q3 		$622 Hold
18
– – ﹤0.01% 667
2023
Q2 		$833 Hold
18
– – ﹤0.01% 649
2023
Q1 		$827 Hold
18
– – ﹤0.01% 764
2022
Q4 		$1.45K Hold
18
– – ﹤0.01% 748
2022
Q3 		$1K Hold
18
– – ﹤0.01% 891
2022
Q2 		$1K Hold
18
– – ﹤0.01% 918
2022
Q1 		$1K Hold
18
– – ﹤0.01% 982
2021
Q4 		$3K Buy
+18
New +$3.23K ﹤0.01% 941

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Washington Trust Advisors's STRO Position: Q1 2024 in Review

Washington Trust Advisors sold out of Sutro Biopharma (STRO) in Q1 2024, closing a stake of 18 shares — an estimated $768 sold.

Washington Trust Advisors first reported a position in STRO in Q4 2021 and held it in 9 quarters. The position peaked at $3K in Q4 2021. 117 funds tracked by Wall St. Rank hold STRO as of Q1 2024.

  • Washington Trust Advisors reported no remaining Sutro Biopharma position as of Q1 2024 after selling out during the quarter.
  • Washington Trust Advisors sold 18 Sutro Biopharma shares in Q1 2024, an estimated $768.
  • Washington Trust Advisors first reported a position in Sutro Biopharma in Q4 2021 and held it in 9 quarters.
  • Washington Trust Advisors's Sutro Biopharma position peaked at $3K in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2024.

Based on Washington Trust Advisors's 13F filing for Q1 2024, filed 7 May 2024.